Debiopharm International Sa

This study tested an experimental oral drug (Debio 0123) combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had worsened after prior platinum-based treatment. The goal was to find the safest dose and check for side effects and early signs of t…

This early-phase study tested a new formulation of octreotide that lasts 12 weeks in people with acromegaly or certain neuroendocrine tumors. The goal was to measure how the drug moves through the body and check its safety. The study was terminated early, so results are limited.

This early-phase study tested a new drug, RP-6306, combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to find a safe dose and check for side effects. The study was terminated earl…

This study tested a new antibiotic called afabicin for people with bone or joint infections caused by staph bacteria. It compared afabicin to standard antibiotics to see if it was safe and worked well. The study was stopped early, but the goal was to find a better treatment optio…

This early-phase study tested a new drug (Debio 0123) combined with standard chemotherapy in 34 adults whose small cell lung cancer returned after prior platinum-based treatment. The goal was to find a safe dose and check for side effects. The study was terminated early, so resul…

This early-stage study tested a new drug (RP-6306) combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors, including colorectal, GI, and esophageal cancers that had stopped responding to other treatments. The main goals were to check safety, find th…